SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

Contributed by: GlobeNewswire

Tags

Health

More Like This

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation